Literature DB >> 21179286

Postoperative high-dose intravenous iron sucrose with low dose erythropoietin therapy after total hip replacement.

Jiyeol Yoon1, Sungmin Kim, Soo Chan Lee, Hongsub Lim.   

Abstract

Erythropoietin combined with parenteral iron sucrose therapy is an alternative to blood transfusion in anemic patients. It was shown to be effective in surgical patients in several previous studies when used in conjunction with other methods. However, there are no guidelines about safety limits in dosage amounts or intervals. In this study, we report a case of significant postoperative hemorrhage managed with high dose parenteral iron sucrose, low dose erythropoietin, vitamin B(12), vitamin C, and folic acid. An 80-year-old female patient presented for severe anemia after a total hip arthroplasty and refused an allogenic blood transfusion as treatment. The preoperative hemoglobin of 12.2 g/dL decreased to 5.3 g/dL postoperatively. She received the aforementioned combination of iron sucrose, erythropoietin, and vitamins. A total of 1,500 mg of intravenous iron sucrose was given postoperatively for 6 consecutive days. Erythropoietin was also administered at 2,000 IU every other day for a total of 12,000 IU. The patient was discharged in good condition on the twelfth postoperative day with a hemoglobin of 8.5 g/dL. Her hemoglobin was at 11.2 g/dL on the twentieth postoperative day.

Entities:  

Keywords:  Arthroplasty; Epoetin alpha; Ferric oxide, saccharated

Mesh:

Substances:

Year:  2010        PMID: 21179286      PMCID: PMC2997977          DOI: 10.3904/kjim.2010.25.4.454

Source DB:  PubMed          Journal:  Korean J Intern Med        ISSN: 1226-3303            Impact factor:   2.884


  20 in total

1.  Suspected iron dextran-related adverse drug events in hemodialysis patients.

Authors:  R Fletes; J M Lazarus; J Gage; G M Chertow
Journal:  Am J Kidney Dis       Date:  2001-04       Impact factor: 8.860

2.  Aprotinin in major orthopedic surgery: a systematic review of randomized controlled trials.

Authors:  Toshiya Shiga; Zen'ichiro Wajima; Tetsuo Inoue; Atsuhiro Sakamoto
Journal:  Anesth Analg       Date:  2005-12       Impact factor: 5.108

Review 3.  Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise.

Authors:  M Brines; A Cerami
Journal:  Kidney Int       Date:  2006-05-31       Impact factor: 10.612

4.  Perioperative intravenous iron, with or without erythropoietin, plus restrictive transfusion protocol reduce the need for allogeneic blood after knee replacement surgery.

Authors:  Jorge Cuenca; José A García-Erce; Fernando Martínez; Luis Pérez-Serrano; Antonio Herrera; Manuel Muñoz
Journal:  Transfusion       Date:  2006-07       Impact factor: 3.157

5.  Perioperative intravenous iron preserves iron stores and may hasten the recovery from post-operative anaemia after knee replacement surgery.

Authors:  J A García-Erce; J Cuenca; F Martínez; R Cardona; L Pérez-Serrano; M Muñoz
Journal:  Transfus Med       Date:  2006-10       Impact factor: 2.019

Review 6.  Hepcidin--a regulator of intestinal iron absorption and iron recycling by macrophages.

Authors:  Tomas Ganz
Journal:  Best Pract Res Clin Haematol       Date:  2005-06       Impact factor: 3.020

7.  Intravenous iron preparations and ascorbic acid: effects on chelatable and bioavailable iron.

Authors:  Brigitte Sturm; Hildegard Laggner; Nina Ternes; Hans Goldenberg; Barbara Scheiber-Mojdehkar
Journal:  Kidney Int       Date:  2005-03       Impact factor: 10.612

8.  Erythropoietin-receptor agonists in critically ill patients: a meta-analysis of randomized controlled trials.

Authors:  Ryan Zarychanski; Alexis F Turgeon; Lauralyn McIntyre; Dean A Fergusson
Journal:  CMAJ       Date:  2007-09-05       Impact factor: 8.262

9.  Efficacy and safety of epoetin alfa in critically ill patients.

Authors:  Howard L Corwin; Andrew Gettinger; Timothy C Fabian; Addison May; Ronald G Pearl; Stephen Heard; Robert An; Peter J Bowers; Paul Burton; Mark A Klausner; Michael J Corwin
Journal:  N Engl J Med       Date:  2007-09-06       Impact factor: 91.245

Review 10.  Erythropoietin and treatment of non-anemic conditions--cardiovascular protection.

Authors:  Danilo Fliser; Hermann Haller
Journal:  Semin Hematol       Date:  2007-07       Impact factor: 3.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.